Skip to main content
Premium Trial:

Request an Annual Quote

Cognia Licenses ITI Technology to Build Drug-Discovery Database

NEW YORK (GenomeWeb News) – ITI Life Sciences has licensed its data-mining technology to bioinformatics company Cognia to develop a drug-discovery database, the companies said today.
 
Cognia’s European branch, Cognia EU, worked with an ITI research program and with the University of Edinburgh’s School of Informatics to develop the technology, the companies said.
 
Under the agreement, ITI will receive royalties from sales of the resulting product. ITI said these proceeds will be re-invested in the ITI Life Sciences Text Mining research program, a 3-year initiative that is scheduled to end in one year.
 
ITI said it expects to sign more licensing agreements with technology developed under this program.  
 
The companies also said they plan to sign a permanent agreement later this year.
 
Cognia said it can deploy and commercialize the IP immediately, and said it expects to create “numerous databases” from the text-mining program.
 
Financial terms of the agreement were not released.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.